FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051805801> ?p ?o ?g. }

• W2051805801 endingPage "1392" @default.
• W2051805801 startingPage "1384" @default.
• W2051805801 abstract "BACKGROUND The growth of breast carcinoma is promoted by autocrine growth factors such as the bombesin (BN)-like peptides and epidermal growth factor (EGF). The stimulatory action of BN-like peptides can be blocked by the use of BN/gastrin-releasing peptide (GRP) antagonists. METHODS The authors investigated the effects of synthetic BN/GRP antagonists RC-3095 and RC-3940-II on tumor growth and the expression of mRNA for EGF receptors and three BN receptor subtypes in MDA-MB-468 human breast carcinoma. Athymic nude mice with xenografts of MDA-MB-468 human breast carcinoma were injected subcutaneously for 6 weeks with RC-3940-II at doses of 20 or 40 μg/day. In another study, the effects of RC-3940-II and RC-3095 were compared. RESULTS RC-3940-II caused a significant and dose-dependent growth inhibition of MDA-MB-468 tumors in nude mice; therapy with either dose of RC-3940-II significantly (P < 0.01) reduced the mean final tumor volume and weight compared with controls. RC-3940-II induced a persistent regression of > 50% of all tumors. One of 3 tumors treated with 20 μg of RC-3940-II and 3 of 5 tumors treated with 40 μg were found to have regressed completely by the end of the study. When RC-3940-II and RC-3095 were compared at the dose of 20 μg/day, both powerfully suppressed growth of MDA-MB-468 tumors, with RC-3940-II causing a complete regression of 2 tumors and RC-3095 a complete regression of 1 tumor. Receptor analyses of untreated MDA-MB-468 tumors revealed an overexpression of EGF receptors and two classes of binding sites for BN/GRP. mRNAs for receptors of GRP, neuromedin B, and BN receptor subtype-3 were detected by reverse transcriptase-polymerase chain reaction. CONCLUSIONS A virtual arrest of growth or regression of MDA-MB-468 human breast carcinoma after therapy with RC-3940-II and RC-3095 indicates that these BN/GRP antagonists could provide a new treatment modality for breast tumors expressing BN and EGF receptors. Cancer 2000;88:1384–92. © 2000 American Cancer Society." @default.
• W2051805801 created "2016-06-24" @default.
• W2051805801 creator A5008707617 @default.
• W2051805801 creator A5010028400 @default.
• W2051805801 creator A5019624736 @default.
• W2051805801 creator A5020698714 @default.
• W2051805801 creator A5063861158 @default.
• W2051805801 creator A5065215059 @default.
• W2051805801 creator A5087230640 @default.
• W2051805801 date "2000-03-15" @default.
• W2051805801 modified "2023-09-23" @default.
• W2051805801 title "Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II" @default.
• W2051805801 cites W1537449868 @default.
• W2051805801 cites W1894641937 @default.
• W2051805801 cites W1964445130 @default.
• W2051805801 cites W1967097978 @default.
• W2051805801 cites W1969257489 @default.
• W2051805801 cites W1977908335 @default.
• W2051805801 cites W1988763385 @default.
• W2051805801 cites W1995980478 @default.
• W2051805801 cites W2008814271 @default.
• W2051805801 cites W2019691808 @default.
• W2051805801 cites W2025497409 @default.
• W2051805801 cites W2031956553 @default.
• W2051805801 cites W2039331787 @default.
• W2051805801 cites W2041298584 @default.
• W2051805801 cites W2043813981 @default.
• W2051805801 cites W2044379086 @default.
• W2051805801 cites W2047607406 @default.
• W2051805801 cites W2049887725 @default.
• W2051805801 cites W2052847038 @default.
• W2051805801 cites W2066952573 @default.
• W2051805801 cites W2068776651 @default.
• W2051805801 cites W2072577105 @default.
• W2051805801 cites W2086825126 @default.
• W2051805801 cites W2093397667 @default.
• W2051805801 cites W2101679711 @default.
• W2051805801 cites W2114082871 @default.
• W2051805801 cites W2137848795 @default.
• W2051805801 cites W2157145674 @default.
• W2051805801 cites W2167549601 @default.
• W2051805801 cites W74695622 @default.
• W2051805801 cites W2007141799 @default.
• W2051805801 doi "https://doi.org/10.1002/(sici)1097-0142(20000315)88:6<1384::aid-cncr16>3.0.co;2-q" @default.
• W2051805801 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10717621" @default.
• W2051805801 hasPublicationYear "2000" @default.
• W2051805801 type Work @default.
• W2051805801 sameAs 2051805801 @default.
• W2051805801 citedByCount "33" @default.
• W2051805801 countsByYear W20518058012012 @default.
• W2051805801 countsByYear W20518058012014 @default.
• W2051805801 countsByYear W20518058012015 @default.
• W2051805801 countsByYear W20518058012016 @default.
• W2051805801 countsByYear W20518058012017 @default.
• W2051805801 countsByYear W20518058012018 @default.
• W2051805801 countsByYear W20518058012019 @default.
• W2051805801 countsByYear W20518058012021 @default.
• W2051805801 crossrefType "journal-article" @default.
• W2051805801 hasAuthorship W2051805801A5008707617 @default.
• W2051805801 hasAuthorship W2051805801A5010028400 @default.
• W2051805801 hasAuthorship W2051805801A5019624736 @default.
• W2051805801 hasAuthorship W2051805801A5020698714 @default.
• W2051805801 hasAuthorship W2051805801A5063861158 @default.
• W2051805801 hasAuthorship W2051805801A5065215059 @default.
• W2051805801 hasAuthorship W2051805801A5087230640 @default.
• W2051805801 hasConcept C118303440 @default.
• W2051805801 hasConcept C121608353 @default.
• W2051805801 hasConcept C126322002 @default.
• W2051805801 hasConcept C128240485 @default.
• W2051805801 hasConcept C134018914 @default.
• W2051805801 hasConcept C170493617 @default.
• W2051805801 hasConcept C185592680 @default.
• W2051805801 hasConcept C2776998989 @default.
• W2051805801 hasConcept C2778448772 @default.
• W2051805801 hasConcept C2779707156 @default.
• W2051805801 hasConcept C3018521938 @default.
• W2051805801 hasConcept C530470458 @default.
• W2051805801 hasConcept C55493867 @default.
• W2051805801 hasConcept C62112901 @default.
• W2051805801 hasConcept C71924100 @default.
• W2051805801 hasConceptScore W2051805801C118303440 @default.
• W2051805801 hasConceptScore W2051805801C121608353 @default.
• W2051805801 hasConceptScore W2051805801C126322002 @default.
• W2051805801 hasConceptScore W2051805801C128240485 @default.
• W2051805801 hasConceptScore W2051805801C134018914 @default.
• W2051805801 hasConceptScore W2051805801C170493617 @default.
• W2051805801 hasConceptScore W2051805801C185592680 @default.
• W2051805801 hasConceptScore W2051805801C2776998989 @default.
• W2051805801 hasConceptScore W2051805801C2778448772 @default.
• W2051805801 hasConceptScore W2051805801C2779707156 @default.
• W2051805801 hasConceptScore W2051805801C3018521938 @default.
• W2051805801 hasConceptScore W2051805801C530470458 @default.
• W2051805801 hasConceptScore W2051805801C55493867 @default.
• W2051805801 hasConceptScore W2051805801C62112901 @default.
• W2051805801 hasConceptScore W2051805801C71924100 @default.
• W2051805801 hasIssue "6" @default.
• W2051805801 hasLocation W20518058011 @default.
• W2051805801 hasLocation W20518058012 @default.

• next